Access community-based treatments for coronavirus (COVID-19)

AI Summary

The COVID-19 Antivirals and Therapeutics Taskforce, operating under NHS England and devolved administrations, concluded its operations on March 31, 2023, in alignment with the UK government’s strategy for 'living with COVID-19.' This transition marks the end of temporary pandemic measures and the integration of antiviral treatments into routine healthcare frameworks. Historically, the taskforce managed treatment access through the University of Oxford's PANORAMIC study and regional Medicines Delivery Units (CMDUs). While these access points remain, the regulatory landscape has shifted significantly. Specifically, the prescription waiver for COVID-19 antivirals ended on the taskforce's closure date. Patients must now pay standard NHS prescription charges for community-based treatments unless they qualify for exemptions based on age, income, or specific health conditions. However, medications provided through ongoing clinical trials like HEAL remain free of charge. Required actions for clinicians and eligible high-risk patients include adhering to updated eligibility criteria established by the COVID-19 Therapeutics Clinical Review Panel and monitoring the NHS website for pathway changes scheduled for 2023. This summary highlights the shift from universal free access to standard NHS charging structures, requiring patients to verify their benefit status for continued financial support. NHS England will continue publishing weekly treatment data to maintain oversight of drug deployment across hospital and community settings.